I-2 imidazoline receptor

David Finn

doi:10.1016/B978-008055232-3.60378-2

I-2 imidazoline receptor

David Finn

Pharmacology

Research output: Chapter in Book or Conference Publication/Proceeding › Chapter › peer-review

Abstract

The I₂ binding site was first identified on the basis of its preference for binding [³H]idazoxan over [³H]clonidine. Recent years have seen the development of selective, high-affinity ligands allowing more detailed characterization of the I₂ binding site. I₂ binding sites are more ubiquitous than I₁ or I₃ binding sites and are distributed in the brain and periphery. There has been considerable interest in I₂ binding sites as potential therapeutic targets in the treatment of neuropsychiatric disorders..

Original language	English
Title of host publication	xPharm
Subtitle of host publication	The Comprehensive Pharmacology Reference
Publisher	Elsevier Inc.
Pages	1-7
Number of pages	7
ISBN (Print)	9780080552323
DOIs	https://doi.org/10.1016/B978-008055232-3.60378-2
Publication status	Published - 2007

Access to Document

10.1016/B978-008055232-3.60378-2

Cite this

@inbook{0766fb71be6b4c2b9eb9ab302223b411,

title = "I-2 imidazoline receptor",

abstract = "The I2 binding site was first identified on the basis of its preference for binding [3H]idazoxan over [3H]clonidine. Recent years have seen the development of selective, high-affinity ligands allowing more detailed characterization of the I2 binding site. I2 binding sites are more ubiquitous than I1 or I3 binding sites and are distributed in the brain and periphery. There has been considerable interest in I2 binding sites as potential therapeutic targets in the treatment of neuropsychiatric disorders..",

author = "David Finn",

year = "2007",

doi = "10.1016/B978-008055232-3.60378-2",

language = "English",

isbn = "9780080552323",

pages = "1--7",

booktitle = "xPharm",

publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - I-2 imidazoline receptor

AU - Finn, David

PY - 2007

Y1 - 2007

N2 - The I2 binding site was first identified on the basis of its preference for binding [3H]idazoxan over [3H]clonidine. Recent years have seen the development of selective, high-affinity ligands allowing more detailed characterization of the I2 binding site. I2 binding sites are more ubiquitous than I1 or I3 binding sites and are distributed in the brain and periphery. There has been considerable interest in I2 binding sites as potential therapeutic targets in the treatment of neuropsychiatric disorders..

AB - The I2 binding site was first identified on the basis of its preference for binding [3H]idazoxan over [3H]clonidine. Recent years have seen the development of selective, high-affinity ligands allowing more detailed characterization of the I2 binding site. I2 binding sites are more ubiquitous than I1 or I3 binding sites and are distributed in the brain and periphery. There has been considerable interest in I2 binding sites as potential therapeutic targets in the treatment of neuropsychiatric disorders..

UR - http://www.scopus.com/inward/record.url?scp=84884102700&partnerID=8YFLogxK

U2 - 10.1016/B978-008055232-3.60378-2

DO - 10.1016/B978-008055232-3.60378-2

M3 - Chapter

AN - SCOPUS:84884102700

SN - 9780080552323

SP - 1

EP - 7

BT - xPharm

PB - Elsevier Inc.

ER -

I-2 imidazoline receptor

Abstract

Access to Document

Other files and links

Fingerprint

Cite this